NAVBQ (Navidea Biopharmaceuticals) ROC %: -257.95% (As of Sep. 2023)


NAVBQ Navidea Biopharmaceuticals Inc NAVBQ
16 GF Score
Price $0.00
View Full Analysis

What is Navidea Biopharmaceuticals ROC %?

Navidea Biopharmaceuticals NAVBQ 16 ROC % is -257.95% as of Sep. 2023. GuruFocus rates NAVBQ with a GF Score™ of 16/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Navidea Biopharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Sep. 2023 was -257.95%.

As of today (2026-06-25), Navidea Biopharmaceuticals's WACC % is 0.00%. Navidea Biopharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Navidea Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Navidea Biopharmaceuticals  (OTCPK:NAVBQ) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Navidea Biopharmaceuticals's WACC % is 0.00%. Navidea Biopharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Navidea Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Navidea Biopharmaceuticals ROC % Related Terms

Navidea Biopharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Navidea Biopharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navidea Biopharmaceuticals ROC % Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -144.20 -351.15 -370.11 -383.83 -429.23

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,152.74 -482.26 -343.36 -342.21 -257.95
NAVBQ
16GF Score
Navidea Biopharmaceuticals Inc NAVBQ
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Navidea Biopharmaceuticals ROC % Calculation

Navidea Biopharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-14.051 * ( 1 - 0% )/( (3.227 + 3.32)/ 2 )
=-14.051/3.2735
=-429.23 %

where

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6.645 - 3.335 - ( 4.231 - max(0, 5.3 - 5.383+4.231))
=3.227

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.372 - 7.79 - ( 1.996 - max(0, 9.942 - 3.204+1.996))
=3.32

Navidea Biopharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-8.524 * ( 1 - 0% )/( (3.353 + 3.256)/ 2 )
=-8.524/3.3045
=-257.95 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.22 - 6.168 - ( 6.144 - max(0, 8.306 - 7.005+6.144))
=3.353

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.699 - 5.919 - ( 3.865 - max(0, 7.979 - 4.503+3.865))
=3.256

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -257.95% mean?
Navidea Biopharmaceuticals (NAVBQ) has a ROC % of -257.95% as of Sep. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Navidea Biopharmaceuticals and its competitors.
Is Navidea Biopharmaceuticals' ROC % too high?
Navidea Biopharmaceuticals' current ROC % is -257.95%. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' ROC % compare to PKBO and RSPI?
Navidea Biopharmaceuticals' ROC % of -257.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Navidea Biopharmaceuticals and its competitors. Navidea Biopharmaceuticals's current ROC % is -257.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current ROC % of -257.95%. The current ROC % is -257.95%. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current ROC % is -257.95% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Navidea Biopharmaceuticals Business Description

Address 4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score

Get the complete analysis for NAVBQ

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price